On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, Marketbeat.com ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Monday, February 3rd. Leerink ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

See "Use of Non-GAAP Financial Information". U.S. revenues increased 9% to $8.6 billion, primarily driven by higher demand for the Growth Portfolio and Eliquis, partially offset by the impact of ...